Gaps found in gray areas like adverse events reported on blogs and interactive web events
As the FDA focuses more of its attention on post-marketing surveillance for adverse events (AE), a new study shines light on the reporting practices of some of the largest biopharmaceutical companies in the US.
Best Practices LLC, a research and consulting company, surveyed drug safety executives from 15 biopharmaceutical companies, including Amgen, Boehringer Ingelheim, Novartis, Novo Nordisk and Takeda, on a variety of topics related to post-marketing surveillance of adverse drug events. Best Practices says the study’s objective was to “identify best practices for post-marketing surveillance within the United States, as well as the processes for assessing reports of adverse events, follow-up activities and compliance training.”
Among the findings:
The report, entitled “Best Practices for Post-Marketing Surveillance of Adverse Events within the US,” is available at www.best-in-class.com.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Boosting Patient Adherence: The Power of Clinical Support Programs
October 3rd 2024In this podcast, we speak with Amanda Scholz, UBC Senior Clinical Program Manager, MHA, BSN, RN as we discuss the important role that clinical adherence programs play in empowering patients and bolster persistence to prescribed life-changing medications throughout their journey.